# Current status of cervical cancer prevention and screening in Myanmar

Source: https://onco.cc/key-papers/paper-thinn-cervical-screening-myanmar-2023/  
OnCo record `paper-thinn-cervical-screening-myanmar-2023` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A short commentary by Yangon gynaecological and medical oncologists on how Myanmar introduced vaccination of 9-year-old girls against human papillomavirus in 2020 and began screening for the virus in 2021 and 2022.

## Summary

Published as a mini commentary, "Current Status of Cervical Cancer Prevention and Screening in Myanmar", by clinicians at Yangon Central Women's Hospital and the Universities of Medicine (1) and (2), Yangon. It describes Myanmar's selection in 2017 for the United Nations Global Joint Programme on cervical cancer prevention and control, the screening and treatment guidelines launched in 2018, a National Cervical Cancer Prevention and Control Program from 2019, and the introduction of the vaccine in 2020.

## Fields

- Kind: Key paper
- Last checked: 2026-11-11
- Journal: South Asian Journal of Cancer
- Year: 2023
- DOI: 10.1055/s-0043-1764212
- Authors: Thinn MM, Aung S, Aung A, Tun NM
- Findings: The vaccine against human papillomavirus entered the Expanded Programme on Immunization in 2020 as its 13th new vaccine, for a single age cohort of 9-year-old girls.; Planned as school-based, it was given in the community because schools were closed during the COVID-19 pandemic, and more than 90% of 9-year-old girls received a first dose in 2020.; The 2018 guidelines adopt a hybrid approach: visual inspection with acetic acid where staff allow, testing for the virus, including self-collected samples, in rural areas, and ablative treatment of women who test positive.; Screening planned for 16 townships in 2020 was halted by the pandemic; in late 2021 and early 2022 pilot screening with the careHPV test took place in 9 of 17 states and regions.
- What it means: It records the design and early delivery of Myanmar's cervical cancer programme as described by clinicians in Yangon.
- Caveats: A commentary, not a systematic study; coverage figures are quoted from other sources.; It gives Yangon's 2018 cervical cancer rate as 19.5 per 100,000 where a 2025 review gives 19.3.

## Sources

- South Asian J Cancer 2023: https://doi.org/10.1055/s-0043-1764212
- PubMed: https://pubmed.ncbi.nlm.nih.gov/36851926/
- Europe PMC full text: https://europepmc.org/article/PMC/PMC9966159

## Connected records

- key papers: [A review of human papillomavirus prevalence and cervical cancer in Myanmar](https://onco.cc/key-papers/paper-win-hpv-cervical-cancer-myanmar-review-2025/)
- technologies: [HPV & HBV vaccination](https://onco.cc/technologies/hpv-vaccine/)
- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- institutions: [Nay Pyi Taw Cancer Registry (population-based), Myanmar](https://onco.cc/institutions/nay-pyi-taw-cancer-registry/)

---
JSON: https://onco.cc/api/v1/entities/paper-thinn-cervical-screening-myanmar-2023.json